Barclays
ONC

Barclays’s BeOne Medicines Ltd ONC Stock Holding History

Barclays’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.03M Buy
30,400
+19,900
+190% +$6.44M ﹤0.01% 1511
2025
Q4 		$3.19M Sell
10,500
-3,000
-22% -$982K ﹤0.01% 2592
2025
Q3 		$4.6M Buy
+13,500
New +$4.1M ﹤0.01% 2267
2024
Q4 		– Sell
-57,000
Closed -$12.8M – 5537
2024
Q3 		$12.8M Buy
+57,000
New +$10.3M ﹤0.01% 1313
2024
Q1 		– Sell
-15,000
Closed -$2.71M – 5426
2023
Q4 		$2.71M Buy
+15,000
New +$2.71M ﹤0.01% 2665
2018
Q4 		– Sell
-30,000
Closed -$5.17M – 7411
2018
Q3 		$5.17M Buy
+30,000
New +$5.04M ﹤0.01% 1786

Other funds holding ONC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Barclays's ONC Position: Q1 2026 in Review

Barclays increased its BeOne Medicines Ltd (ONC) stake by 1.7% in Q1 2026, buying an estimated $136K and bringing the position to 25,222 shares worth $7.49M. The position accounts for ﹤0.01% of the portfolio, ranked #1600.

Barclays first reported a position in ONC in Q4 2016 and has held it in 38 quarters since. The position peaked at $19.7M in Q4 2020. 281 funds tracked by Wall St. Rank hold ONC as of Q1 2026.

  • Barclays held 25,222 shares of BeOne Medicines Ltd worth $7.49M as of Q1 2026.
  • Barclays bought 421 BeOne Medicines Ltd shares in Q1 2026, an estimated $136K.
  • BeOne Medicines Ltd made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #1600 holding.
  • Barclays first reported a position in BeOne Medicines Ltd in Q4 2016 and has held it in 38 quarters since.
  • Barclays's BeOne Medicines Ltd position peaked at $19.7M in Q4 2020.
  • 281 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.